Literature DB >> 3462444

C-reactive protein during chemotherapy for acute leukemia with special reference to non-infective causes of fever.

S Grützmeier, H von Schenck.   

Abstract

C-reactive protein, CRP, was followed longitudinally in 41 patients being treated for acute leukemia. It was analysed by a rapid (2-h) immunochemical assay in a laser-nephelometer. The cytostatic treatment given either intravenously or intrathecally did not cause any CRP increase with the exception of 7% of the treatment courses, given to 3 patients, and neither did transfusion reactions. The patients had altogether 117 febrile episodes. During 44 episodes with evidence of bacterial or fungal infection, CRP increased above the reference value (90 mg l-1). The same observation was made during 37 febrile episodes with clinically probable infections. CRP remained within the reference value when fever was caused by virus infections or occurring for unknown reasons.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3462444     DOI: 10.1007/BF02934556

Source DB:  PubMed          Journal:  Med Oncol Tumor Pharmacother        ISSN: 0736-0118


  10 in total

1.  Immunochemical quantitation of antigens by single radial immunodiffusion.

Authors:  G Mancini; A O Carbonara; J F Heremans
Journal:  Immunochemistry       Date:  1965-09

2.  Moderate dose methotrexate, vincristine, asparaginase, and dexamethasone for treatment of adult acute lymphocytic leukemia.

Authors:  R J Esterhay; P H Wiernik; W R Grove; S D Markus; M N Wesley
Journal:  Blood       Date:  1982-02       Impact factor: 22.113

Review 3.  C-reactive protein and the acute phase response.

Authors:  H Gewurz; C Mold; J Siegel; B Fiedel
Journal:  Adv Intern Med       Date:  1982

4.  C-reactive protein for rapid diagnosis of infection in leukaemia.

Authors:  P H Mackie; R A Crockson; J Stuart
Journal:  J Clin Pathol       Date:  1979-12       Impact factor: 3.411

5.  C-reactive protein fifty years on.

Authors:  M B Pepys
Journal:  Lancet       Date:  1981-03-21       Impact factor: 79.321

6.  Control of the acute phase response. Serum C-reactive protein kinetics after acute myocardial infarction.

Authors:  I Kushner; M L Broder; D Karp
Journal:  J Clin Invest       Date:  1978-02       Impact factor: 14.808

7.  Serum C-reactive protein levels in the management of infection in acute leukaemia.

Authors:  I D Starke; F C de Beer; J P Donnelly; D Catovsky; J M Goldman; D A Galton; M B Pepys
Journal:  Eur J Cancer Clin Oncol       Date:  1984-03

Review 8.  Interleukin-1.

Authors:  C A Dinarello
Journal:  Rev Infect Dis       Date:  1984 Jan-Feb

9.  High remission-induction rate in acute myeloid leukaemia.

Authors:  R P Gale; M J Cline
Journal:  Lancet       Date:  1977-03-05       Impact factor: 79.321

10.  Serial study of C-reactive protein during infection in leukaemia.

Authors:  P E Rose; S A Johnsdon; M Meakin; P H Mackie; J Stuart
Journal:  J Clin Pathol       Date:  1981-03       Impact factor: 3.411

  10 in total
  5 in total

1.  CRP concentration in a patient with acute leukaemia and bone marrow infarction.

Authors:  S Grützmeier; C Malm
Journal:  Med Oncol Tumor Pharmacother       Date:  1988

2.  Value of measurement of C-reactive protein in febrile patients with hematological malignancies.

Authors:  E Rintala; K Irjala; J Nikoskelainen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-11       Impact factor: 3.267

3.  Acute phase reaction during chemotherapy in small cell lung cancer.

Authors:  R Milroy; D Shapiro; A Shenkin; S W Banham
Journal:  Br J Cancer       Date:  1989-06       Impact factor: 7.640

4.  C-reactive protein (CRP) but not the related pentraxins serum amyloid P and PTX3 inhibits the proliferation and induces apoptosis of the leukemia cell line Mono Mac 6.

Authors:  Wensheng Chen; Darrell Pilling; Richard H Gomer
Journal:  BMC Immunol       Date:  2017-12-04       Impact factor: 3.615

5.  Characteristics of febrile patients with normal white blood cell counts and high C-reactive protein levels in an emergency department.

Authors:  Kuan-Ting Liu; Tzeng-Jih Lin; Hon-Man Chan
Journal:  Kaohsiung J Med Sci       Date:  2008-05       Impact factor: 2.744

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.